NASDAQ:RVNCRevance Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Revance Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $21.32 -0.73 (-3.31 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$21.13Now: $21.32▼$22.4150-Day Range$14.80MA: $18.11▼$21.4652-Week Range$9.88Now: $21.32▼$27.97Volume250,700 shsAverage Volume824,427 shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/ABeta1.55 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.63, Revance Therapeutics has a potential upside of 34.3% from its current price of $21.32.Amount of Analyst CoverageRevance Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesRevance Therapeutics has received 348 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRevance Therapeutics has received 322 “underperform” votes. (Add your “underperform” vote.)Community SentimentRevance Therapeutics has received 51.94% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote “Outperform” if you believe RVNC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions86.63% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($4.44) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevance Therapeutics has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVNC Previous Symbol CUSIPN/A CIK1479290 Webwww.revance.com Phone510-742-3400Debt Debt-to-Equity Ratio0.64 Current Ratio12.45 Quick Ratio12.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$410,000.00 Price / Sales2,966.70 Cash FlowN/A Price / Cash FlowN/A Book Value$5.41 per share Price / Book3.94Profitability EPS (Most Recent Fiscal Year)($3.67) Net Income$-159,430,000.00 Net MarginsN/A Return on Equity-85.18% Return on Assets-49.78%Miscellaneous Employees170 Outstanding Shares57,052,000Market Cap$1.22 billion Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:RVNC Rates by TradingView Receive RVNC News and Ratings via Email Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions How has Revance Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RVNC stock has increased by 18.6% and is now trading at $21.32. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Revance Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Revance Therapeutics. When is Revance Therapeutics' next earnings date? Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Revance Therapeutics. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics Inc (NASDAQ:RVNC) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.24. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.15 million. View Revance Therapeutics' earnings history. What price target have analysts set for RVNC? 9 Wall Street analysts have issued 1 year price targets for Revance Therapeutics' stock. Their forecasts range from $15.00 to $40.00. On average, they expect Revance Therapeutics' share price to reach $28.63 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View analysts' price targets for Revance Therapeutics. Has Revance Therapeutics been receiving favorable news coverage? Headlines about RVNC stock have been trending positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Revance Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the stock's share price in the next several days. View the latest news aboutRevance Therapeutics. Who are some of Revance Therapeutics' key competitors? Some companies that are related to Revance Therapeutics include Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), PPD (SDGR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Evotec (EVTCY), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC) and Allakos (ALLK). View all competitors. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), AbbVie (ABBV), Exelixis (EXEL), Myovant Sciences (MYOV), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Nektar Therapeutics (NKTR) and Catalyst Pharmaceuticals (CPRX). Who are Revance Therapeutics' key executives? Revance Therapeutics' management team includes the following people: Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)Dr. Abhay Joshi, Chief Operating Officer (Age 56)Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications What is Revance Therapeutics' stock symbol? Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC." Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (9.86%), BlackRock Inc. (7.03%), JPMorgan Chase & Co. (6.86%), ArrowMark Colorado Holdings LLC (6.64%), Franklin Resources Inc. (6.47%) and Alliancebernstein L.P. (3.88%). Company insiders that own Revance Therapeutics stock include Cyril Allouche and L Daniel Browne. View institutional ownership trends for Revance Therapeutics. Which major investors are selling Revance Therapeutics stock? RVNC stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, NovaQuest Capital Management L.L.C., Wellington Management Group LLP, JPMorgan Chase & Co., Rothschild & Co. Asset Management US Inc., Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, and Morgan Stanley. View insider buying and selling activity for Revance Therapeutics. Which major investors are buying Revance Therapeutics stock? RVNC stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Alliancebernstein L.P., Geode Capital Management LLC, Franklin Resources Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, and State Street Corp. View insider buying and selling activity for Revance Therapeutics. How do I buy shares of Revance Therapeutics? Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Revance Therapeutics' stock price today? One share of RVNC stock can currently be purchased for approximately $21.32. How big of a company is Revance Therapeutics? Revance Therapeutics has a market capitalization of $1.22 billion and generates $410,000.00 in revenue each year. The biopharmaceutical company earns $-159,430,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe. What is Revance Therapeutics' official website? The official website for Revance Therapeutics is www.revance.com. How can I contact Revance Therapeutics? Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
